Stockscreener 앱 받기
1.85
0.00%
0.00
Taysha Gene Therapies Inc 주식(TSHA)의 최신 뉴스
Wellington Management Group LLP Purchases Shares of 463,192 Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - MarketBeat
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Taysha Gene Therapies' SWOT analysis: promising rett syndrome stock faces key tests - Investing.com Canada
Thinking about buying stock in Nikola, Delcath Systems, Taysha G - GuruFocus.com
Fmr LLC Has $37.54 Million Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 6.3%Still a Buy? - MarketBeat
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Taysha Gene Therapies Issues 152,000-Share Stock Option Grant to New Executive Hire - StockTitan
Canadian Imperial Bank of Commerce (CM-N) QuotePress Release - The Globe and Mail
RTW Investments LP Sells 3,853,879 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - MarketBeat
Rett Syndrome Market Forecast: Key Drivers and Opportunities - openPR
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Consensus Price Target from Brokerages - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 6.3%Time to Buy? - MarketBeat
Acuta Capital Partners LLC Cuts Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - MarketBeat
TSHA (Taysha Gene Therapies) Dividend Yield % : 0.00% (As of Nov. 26, 2024) - GuruFocus.com
TSHA (Taysha Gene Therapies) EPS without NRI : $-0.29 (TTM As of Sep. 2024) - GuruFocus.com
Realty Income Corp (O-N) QuotePress Release - The Globe and Mail
Taysha Gene Therapies' SWOT analysis: stock poised for growth in Rett syndrome market - Investing.com
TSHA (Taysha Gene Therapies) Days Inventory : 0.00 (As of Sep. 2024) - GuruFocus.com
Amgen (NASDAQ:AMGN) vs. Taysha Gene Therapies (NASDAQ:TSHA) Head-To-Head Comparison - Defense World
TSHA (Taysha Gene Therapies) 5-Day RSI : 71.01 (As of Nov. 24, 2024) - GuruFocus.com
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 13.8%Here's What Happened - MarketBeat
Recent Analysts’ Ratings Updates for Taysha Gene Therapies (TSHA) - Defense World
Canaccord Genuity Group Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock Price - Defense World
Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat
Expert Outlook: Taysha Gene Therapies Through The Eyes Of 7 Analysts - Benzinga
Taysha Gene Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2024 Earnings Call Transcript - Insider Monkey
RA Capital Management, L.P. Increases Stake in Taysha Gene Thera - GuruFocus.com
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap DownHere's Why - MarketBeat
Hims & Hers stock falls as Amazon launches Telehealth offering - MSN
Avoro Capital Advisors LLC Increases Stake in Taysha Gene Therap - GuruFocus.com
Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Creative Planning Makes New $28,000 Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Hillenbrand Posts Better-Than-Expected Earnings, Joins Beazer Homes, Tapestry, Walt Disney And Other Big Stocks Moving Higher On ThursdayHuntington Ingalls Indus (NYSE:HII) - Benzinga
Taysha Gene Therapies Inc (TSHA) Q3 2024 Earnings Call Highlight - GuruFocus.com
Taysha Gene Therapies Inc (TSHA) Q3 2024 Earnings Call Highlights: Clinical Progress and ... - Yahoo Finance
Taysha Gene Therapies Advances in Rett Syndrome Trials - TipRanks
Earnings call: Taysha Gene Therapies reports on TSHA-102 Rett Syndrome trial By Investing.com - Investing.com South Africa
Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Taysha Gene Reports Strong Safety Data, FDA Approval for TSHA-102 Trials; Net Loss Narrows | TSHA Stock News - StockTitan
Taysha Gene Therapies' SWOT analysis: promising Rett syndrome stock faces pivotal year - Investing.com UK
FMR LLC's Strategic Reduction in Taysha Gene Therapies Inc - GuruFocus.com
Neurogene’s Rett Data Draw Optimism Despite Serious Adverse Event - Citeline News & Insights
Preview: Taysha Gene Therapies's Earnings - Benzinga
JMP Securities Reaffirms "Market Outperform" Rating for Taysha Gene Therapies (NASDAQ:TSHA) - MarketBeat
Piper Sandler expects Taysha Gene to recover, maintains $7 shares target - Investing.com UK
U.S. Stock market top gainers: BTC Digital surges by 68.60%, Revance Therapeutics climbed by 20.00% in early trading - Business Upturn
Piper Sandler stays bullish on Taysha Gene shares, maintains Overweight rating - Investing.com UK
Taysha Gene Therapies' (TSHA) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Taysha Gene Therapies' (TSHA) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Neurogene hits a setback in the clinic, days after fundraise - BioPharma Dive
Analyzing Taysha Gene Therapies (NASDAQ:TSHA) & Gilead Sciences (NASDAQ:GILD) - Defense World
Neurogene plummets 35% on gene therapy trial data for Rett syndrome - Seeking Alpha
Taysha Gene Therapies Inc (NASDAQ: TSHA) Gains 5.63% In Early Trade; What Lies Ahead? - Stocks Register
US Penny Stocks To Watch In November 2024 - Yahoo Finance
Brokerages Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Price Target at $6.38 - Defense World
Taysha Gene Therapies (TSHA) to Release Earnings on Wednesday - MarketBeat
Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13 - The Manila Times
Taysha Gene Therapies to Release Third Quarter 2024 - GlobeNewswire
2.88%
2.65%
자본화:
|
볼륨(24시간):